TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03967886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 20mg
Description: Patients should take drugs an hour before breakfast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
Study: NCT03145337

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FlexHD ADM (Cohort A)
Description: Tissue assisted breast reconstruction with FlexHD pliable perforated ADM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AlloDerm RTU ADM (Cohort B)
Description: Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
Study: NCT03224299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCT - clear
Description: Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCT- tinted
Description: Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Active Control: ChloraPrep® - Hi-Lite Orange® applicator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Negative Control: sterile 0.9% saline applied with single use applicator
Study: NCT02469467

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VS-505
Description: VS-505 is orally administered with meal for 8 weeks
Study: NCT04378062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital nerve procedure
Description: The type of procedure performed on the digital nerve at the time of amputation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital nerve procedure
Description: The type of procedure performed on the digital nerve at the time of amputation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital nerve procedure
Description: The type of procedure performed on the digital nerve at the time of amputation
Study: NCT01299974

Intervention type: OTHER
Group type: OTHER
Intervention: Parents and Residents in Session
Description: Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
Study: NCT02064660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: massager
Description: The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
Study: NCT02846194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief guided imagery
Study: NCT01557998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POC CD4 and Peer Case Management
Description: HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.

Intervention type: DRUG
Group type: OTHER
Intervention: HCV+PWID
Description: Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: HCV+PWID
Description: Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCV+PWID
Description: Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control - No intervention
Study: NCT03586596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Decídetext program
Description: Decídetext participants will be directed to the tablet-based software. Participants will receive an interactive education session that will lead them through language-appropriate, culturally-relevant information about stopping smoking, collection of basic smoking history data, and choices/plans about preparing to quit. Quit plans include: 1) choice of quit date, 2) NRT preference, 3) plan to remove smoking cues, 4) identification of trigger situations and 5) choice of suggested coping strategies. Participant data and choices are used to generate a printed 1-page individualized treatment plan. Tablet components, assessment items, audio narrative, brief multimedia instructional video clips, and the printed treatment plan have been developed to address low-literacy levels.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control
Description: Educational Material provided as of suggested by American Cancer Society and, the National Cancer Institute
Study: NCT02796092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fibered platinum coils

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular plugs
Study: NCT00306917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: coated femoral hip stem
Description: total hip replacement
Study: NCT04081935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: virtual reality (VR) as a distracting intervention could reduce pain and fear during an IV placement for school-age children in the emergent department.
Study: NCT01192217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified thoracoscopic technique
Description: Two-port thoracoscopic technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary mini-thoracotomy
Description: Axillary mini-thoracotomy
Study: NCT01237808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Description: in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
Study: NCT02020096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound and nerve stimulator guided lumbar plexus block
Description: An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.3 to 0.5 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve stimulator guided lumbar plexus block
Description: The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.3 to 0.5 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
Study: NCT03150095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Patients will work with a health coach by telephone
Study: NCT02660333

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin - 11g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: Fructooligosaccharide - 11g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day
Study: NCT01735617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Modified Release Capsules
Description: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
Study: NCT00554892

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bowel preparation
Description: oral laxatives, retrograde enemas

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no preparation bowel
Description: no preparation bowel
Study: NCT02348411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate
Study: NCT04425772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FNC+Standard of Care
Description: FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FNC dummy tablet+Standard of Care
Description: FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
Study: NCT03026413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein antrum modification

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary vein antrum modification
Study: NCT00752609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginesatide
Description: Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
Study: NCT02566330

Intervention type: DEVICE
Intervention: EndoBarrier
Description: The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
Study: NCT02000570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sitting position (neurosurgery)
Study: NCT01474746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
Study: NCT04056013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl Rapide absorbable suture
Description: In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own.
Study: NCT01592890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: \[14C\]-labeled RO4917523, single oral dose
Study: NCT03152578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BetaC Topical Cream
Description: BetaC Topical Cream Cream applied to painful knee area 3 times per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Cream
Description: Placebo Cream applied to painful knee area 3 times per day.
Study: NCT02890875

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol lock

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heparin lock
Study: NCT04238000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
Study: NCT01592890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: \[13C\]-labeled RO4917523, single intravenous tracer dose
Study: NCT02831634

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
Study: NCT01521234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback of daily walking activity
Description: Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
Study: NCT03909191

Intervention type: DIAGNOSTIC_TEST
Intervention: serum HBV RNA
Description: serum HBV RNA level was determined by using HBV-SAT kit at different time point

Intervention type: DIAGNOSTIC_TEST
Intervention: serum HBV RNA
Description: serum HBV RNA level was determined by using HBV-SAT kit at different time point
Study: NCT01239563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antithymocyte globulin
Description: Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Intravenous 20mg, day 0\&4
Study: NCT02052648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Study: NCT03002246

Intervention type: OTHER
Intervention: Ultrasound Examination
Description: Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.

Intervention type: OTHER
Intervention: Ultrasound Examination
Description: Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.

Intervention type: OTHER
Intervention: Ultrasound Examination
Description: Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.
Study: NCT02740686

Intervention type: OTHER
Intervention: Sample collection
Description: Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.

Intervention type: OTHER
Intervention: Sample collection
Description: Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.

Intervention type: OTHER
Intervention: Sample collection
Description: Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.

Intervention type: OTHER
Intervention: Sample collection
Description: Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.
Study: NCT00422019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102 at 10 mg/kg
Description: AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102 at 20 mg/kg
Description: AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
Study: NCT01385384

Intervention type: DEVICE
Group type: OTHER
Intervention: NeuRx RA/4 diaphragmatic pacemaker
Description: Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.~The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.~Sites that provide the optimal response (greater region and magnitude) are noted.~Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed.
Study: NCT01419483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
Study: NCT04195269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Article
Description: 10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.